Compare AUGO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AUGO | GPCR |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.8B |
| IPO Year | 2009 | 2023 |
| Metric | AUGO | GPCR |
|---|---|---|
| Price | $84.91 | $47.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $67.60 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 891.3K | 549.2K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $91.05 | N/A |
| Revenue Next Year | $17.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.11 | $20.04 |
| 52 Week High | $110.32 | $94.90 |
| Indicator | AUGO | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 41.03 |
| Support Level | $78.80 | $46.40 |
| Resistance Level | $91.24 | $56.63 |
| Average True Range (ATR) | 4.12 | 2.26 |
| MACD | -0.59 | -0.59 |
| Stochastic Oscillator | 81.69 | 19.33 |
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.